Hematological Malignancies

• Still a role for watch & wait in asymptomatic pts • Wait for indication of treatment • Combined R-chemo standard; R-CHOPmost often used • No clear superiority of R-CHOP over R-CVP • BR with longer PFS and lower toxicity • R-chemo plus R-maintenance current best option in follicular particularly in relapsed disease • No relevant role for high-dose chemo and ASCT • Perspectives: Bortezomib, Lenalidomide, Obinutuzumab (GA101), Ofatumumab, Temsirolimus, Ibrutinib, Idelalisib, ABT-199 Standard of care in pts with indolent lymphomas